A triumph for physiology driving drug discovery: the potential impact of dipeptidyl peptidase-IV inhibitors in type 2 diabetes.
Donnelly
Richard
R
D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D054873:Dipeptidyl-Peptidase IV Inhibitors; D004345:Drug Industry / Q000639:trends; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D011480:Protease Inhibitors / Q000627:therapeutic use*
D054873:Dipeptidyl-Peptidase IV Inhibitors; D007004:Hypoglycemic Agents; D011480:Protease Inhibitors